Cardiac Dimensions, a Kirkland, Wash., company with a technology to treat heart valve malfunction, has raised $53 million ...

Cardiac Dimensions has secured $53m in a Series E funding round to support its ongoing pivotal trial assessing the company’s mitral valve repair device. The round was led by investment management firm ...

TRILUMINATE's primary endpoint was a hierarchical composite of death from any cause or tricuspid valve surgery, ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

Dear K.T.: Dexfenfluramine, aka Redux (also called "fen-phen" in combination with phentermine), was sold in the 1990s until ...

with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's prespecified goal of 25% to show non-inferiority, according to a ...

At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received ... severe tricuspid regurgitation appears to be safe, significantly reduced symptom ...

JenaValve today announced new results from an expanded cohort receiving its Trilogy transcatheter heart valve (THV) system.

The chordae tendineae (CT), often referred to as the “heart strings,” are thin, tendinous structures that connect the heart ...

A EUROPEAN post-market registry study has demonstrated that tricuspid transcatheter edge-to-edge repair (T-TEER) using the ...

Cardiac Dimensions has about 70 employees globally: 40 in Kirkland, 10 throughout the United States, and 20 in Europe.